At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Canagliflozin Continuous Glucose Monitoring (CANA CGM) Trial: A Pilot Randomized, Double-Blind, Controlled, Crossover Study on the Effects of the SGLT-2 Inhibitor Canagliflozin (vs. the DPP-4 Inhibitor Sitagliptin) on Glucose Variability in Mexican Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
In Brief
A Phase 4 clinical trial evaluating Canagliflozin 300 mg, Sitagliptin 100 mg, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 64 participants across 5 sites.
Detailed Summary
The main purpose of this study is to assess the effects of 4 weeks each of daily treatment with canagliflozin 300 milligram (mg) versus sitagliptin 100 mg as treatment adjuncts to metformin (at stable dosages) on intrapatient glycemic coefficient of variation (CV), expressed as a ratio percentage of standard deviation (SD) to mean glucose levels.
Study Details
Timeline
Interventions
Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.
Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.
Participants will receive metformin at a stable dose of \>= 1500 mg/day throughout the study including the washout period between each intervention.